A Conditional Mutant Deficient in Hypoxanthine-guanine Phosphoribosyltransferase and Xanthine Phosphoribosyltransferase Validates the Purine Salvage Pathway of Leishmania donovani

Jan M. Boitz, Buddy Ullman

Journal of Biological Chemistry · 2006 · 54 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

Leishmania donovani cannot synthesize purines de novo and express a multiplicity of enzymes that enable them to salvage purines from their hosts. Previous efforts to generate an L. donovani strain deficient in both hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) and xanthine phosphoribosyltransferase (XPRT) using gene replacement approaches were not successful, lending indirect support to the hypothesis that either HGPRT or XPRT is crucial for purine salvage by the parasite. We now report the genetic confirmation of this hypothesis through the construction of a conditional Δhgprt/Δxprt mutant strain that exhibits an absolute requirement for 2′-deoxycoformycin, an inhibitor of the leishmanial adenine aminohydrolase enzyme, and either adenine or adenosine as a source of purine. Unlike wild type parasites, the Δhgprt/Δxprt strain cannot proliferate indefinitely without 2′-deoxycoformycin or with hypoxanthine, guanine, xanthine, guanosine, inosine, or xanthosine as the sole purine nutrient. The Δhgprt/Δxprt mutant infects murine bone marrow-derived macrophages <5% as effectively as wild type parasites and cannot sustain an infection. These data establish genetically that either HGPRT or XPRT is absolutely essential for purine acquisition, parasite viability, and parasite infectivity of mouse macrophages, that all exogenous purines are funneled to hypoxanthine and/or xanthine by L. donovani, and that the purine sources within the macrophage to which the parasites have access are HGPRT or XPRT substrates. Leishmania donovani cannot synthesize purines de novo and express a multiplicity of enzymes that enable them to salvage purines from their hosts. Previous efforts to generate an L. donovani strain deficient in both hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) and xanthine phosphoribosyltransferase (XPRT) using gene replacement approaches were not successful, lending indirect support to the hypothesis that either HGPRT or XPRT is crucial for purine salvage by the parasite. We now report the genetic confirmation of this hypothesis through the construction of a conditional Δhgprt/Δxprt mutant strain that exhibits an absolute requirement for 2′-deoxycoformycin, an inhibitor of the leishmanial adenine aminohydrolase enzyme, and either adenine or adenosine as a source of purine. Unlike wild type parasites, the Δhgprt/Δxprt strain cannot proliferate indefinitely without 2′-deoxycoformycin or with hypoxanthine, guanine, xanthine, guanosine, inosine, or xanthosine as the sole purine nutrient. The Δhgprt/Δxprt mutant infects murine bone marrow-derived macrophages <5% as effectively as wild type parasites and cannot sustain an infection. These data establish genetically that either HGPRT or XPRT is absolutely essential for purine acquisition, parasite viability, and parasite infectivity of mouse macrophages, that all exogenous purines are funneled to hypoxanthine and/or xanthine by L. donovani, and that the purine sources within the macrophage to which the parasites have access are HGPRT or XPRT substrates. Leishmania donovani is a protozoan parasite that is the etiologic agent of visceral leishmaniasis, a devastating and often fatal disease in humans. Leishmania spp. are digenetic, existing in both insect vector and mammalian forms. The flagellated, motile, extracellular promastigote proliferates in the midgut of phlebotomine sandfly family members, whereas the nonflagellated, nonmotile, intracellular amastigote resides in phagolysosomes of macrophages and other reticuloendothelial cells within the vertebrate host. Because of the absence of effective vaccines, chemotherapy has offered the only avenue of defense for the treatment and prevention of leishmaniasis and other parasitic diseases. Unfortunately, drug therapy for leishmaniasis is compromised by toxicity, expense, prolonged and invasive routes of administration, and resistance. Thus, the need for new and more efficacious drugs is acute. The institution of an effective parasite-specific therapeutic regimen for the treatment of leishmaniasis, or for that matter any parasitic disease, depends upon exploiting fundamental biochemical or metabolic differences between parasite and host. Perhaps the most striking metabolic disparity between parasites and their mammalian hosts is the avenue by which they synthesize purine nucleotides. Whereas mammalian cells can generate the purine ring de novo, all of the protozoan parasites studied to date are incapable of synthesizing the purine ring (1Marr J.J. Berens R.L. Nelson D.J. Biochim. Biophys. Acta. 1978; 544: 360-371Crossref PubMed Scopus (148) Google Scholar). As a consequence, each genus of parasite has evolved a unique complement of purine salvage enzymes that enables it to scavenge host purines (1Marr J.J. Berens R.L. Nelson D.J. Biochim. Biophys. Acta. 1978; 544: 360-371Crossref PubMed Scopus (148) Google Scholar, 2Looker D.L. Berens R.L. Marr J.J. Mol. Biochem. Parasitol. 1983; 9: 15-28Crossref PubMed Scopus (82) Google Scholar). Leishmania expresses a number of purine salvage enzymes. These enzymes include hypoxanthine-guanine phosphoribosyltransferase (HGPRT), 3The abbreviations used are: HGPRT, hypoxanthine-guanine phosphoribosyltransferase; APRT, adenine phosphoribosyltransferase; XPRT, xanthine phosphoribosyltransferase; AK, adenosine kinase; dCF, 2′-deoxycoformycin; AAH, adenine aminohydrolase; UTR, untranslated region; DME-L, Dulbecco's Modified Eagle-Leishmania; PBS, phosphate-buffered saline. adenine phosphoribosyltransferase (APRT), xanthine phosphoribosyltransferase (XPRT), and adenosine kinase (AK), and the genes encoding all four L. donovani proteins have been isolated and sequenced (3Allen T. Hwang H.Y. Wilson K. Hanson S. Jardim A. Ullman B. Mol Biochem. Parasitol. 1995; 74: 99-103Crossref PubMed Scopus (24) Google Scholar, 4Allen T.E. Hwang H.Y. Jardim A. Olafson R. Ullman B. Mol. Biochem. Parasitol. 1995; 73: 133-143Crossref PubMed Scopus (38) Google Scholar, 5Jardim A. Bergeson S.E. Shih S. Carter N. Lucas R.W. Merlin G. Myler P.J. Stuart K. Ullman B. J. Biol. Chem. 1999; 274: 34403-34410Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 6Sinha K.M. Ghosh M. Das I. Datta A.K. Biochem. J. 1999; 339: 667-673Crossref PubMed Scopus (23) Google Scholar). Interestingly, both HGPRT and XPRT are targeted to the glycosome (7Shih S. Hwang H.Y. Carter D. Stenberg P. Ullman B. J. Biol. Chem. 1998; 273: 1534-1541Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar, 8Zarella-Boitz J.M. Rager N. Jardim A. Ullman B. Mol Biochem. Parasitol. 2004; 134: 43-51Crossref PubMed Scopus (27) Google Scholar), a subcellular organelle unique to Leishmania and related parasites (9Parsons M. Furuya T. Pal S. Kessler P. Mol. Biochem. Parasitol. 2001; 115: 19-28Crossref PubMed Scopus (83) Google Scholar), and this glycosomal localization is mediated by a COOH-terminal tripeptide referred to as the peroxisomal targeting signal 1 (9Parsons M. Furuya T. Pal S. Kessler P. Mol. Biochem. Parasitol. 2001; 115: 19-28Crossref PubMed Scopus (83) Google Scholar). The parasite also accommodates a variety of purine interconversion enzymes including nucleosidases (1Marr J.J. Berens R.L. Nelson D.J. Biochim. Biophys. Acta. 1978; 544: 360-371Crossref PubMed Scopus (148) Google Scholar, 10Koszalka G.W. Krenitsky T.A. J. Biol. Chem. 1979; 254: 8185-8193Abstract Full Text PDF PubMed Google Scholar), IMP branchpoint enzymes, phosphorylases, and deaminases (1Marr J.J. Berens R.L. Nelson D.J. Biochim. Biophys. Acta. 1978; 544: 360-371Crossref PubMed Scopus (148) Google Scholar, 11Kidder G.W. Nolan L.L. Proc. Natl. Acad. Sci. U. S. A. 1979; 76: 3670-3672Crossref PubMed Scopus (41) Google Scholar). Thus, the purine salvage pathway of Leishmania is divagating and redundant, and this metabolic complexity, as well as the diploid nature of the parasite, has hindered a thorough characterization of the pathway. The ability of Leishmania to carry out efficient homologous gene replacement (12Kapler G.M. Coburn C.M. Beverley S.M. Mol. Cell. Biol. 1990; 10: 1084-1094Crossref PubMed Scopus (361) Google Scholar, 13LeBowitz J.H. Coburn C.M. McMahon-Pratt D. Beverley S.M. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 9736-9740Crossref PubMed Scopus (191) Google Scholar) and take up foreign DNAs (14Cruz A. Beverley S.M. Nature. 1990; 348: 171-173Crossref PubMed Scopus (193) Google Scholar), however, can overcome these impediments and enables the genetic dissection of complex metabolic pathways such as that for purine acquisition. Implementing targeted gene replacement strategies, L. donovani promastigotes deficient in HGPRT, APRT, XPRT, and/or AK were created in almost every conceivable combination (5Jardim A. Bergeson S.E. Shih S. Carter N. Lucas R.W. Merlin G. Myler P.J. Stuart K. Ullman B. J. Biol. Chem. 1999; 274: 34403-34410Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 15Hwang H.Y. Gilberts T. Jardim A. Shih S. Ullman B. J. Biol. Chem. 1996; 271: 30840-30846Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar, 16Hwang H.Y. Ullman B. J. Biol. Chem. 1997; 272: 19488-19496Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar), although it was not possible to create a Δhgprt/Δxprt double mutant in any genetic background. These genetic studies underscored our central hypothesis governing purine metabolism that either HGPRT or XPRT is both necessary and sufficient for all of purine acquisition by L. donovani. The inability to create the Δhgprt/Δxprt double knock-out, however, was negative evidence that did not confirm the premise. We have now isolated and characterized a conditional Δhgprt/Δxprt line of L. donovani that was selected by targeted gene replacement in the presence of 2′-deoxycoformycin (dCF), an inhibitor of the leishmanial adenine aminohydrolase (AAH) enzyme (11Kidder G.W. Nolan L.L. Proc. Natl. Acad. Sci. U. S. A. 1979; 76: 3670-3672Crossref PubMed Scopus (41) Google Scholar), and adenine as a source of purine. The creation and characterization of this Δhgprt/Δxprt mutant confirms our main supposition that either HGPRT or XPRT is absolutely essential for purine acquisition and parasite viability. Materials—[8-14C]Adenine (50 mCi/mmol), [8-14C]adenosine (53 mCi/mmol), [8-14C]guanine (55 mCi/mmol), [8-14C]guanosine (50 mCi/mmol), [8-14C]hypoxanthine (51 mCi/mmol), [8-14C]inosine (52 mCi/mmol), and [8-14C]xanthine (53 mCi/mmol) were all purchased from Moravek Biochemicals (Brea, CA). dCF was obtained from the National Cancer Institute (Bethesda, MD). All restriction and DNA-modifying enzymes and all other chemicals and reagents were of the highest quality commercially available. Axenic Parasite Cell Culture—The L. donovani strain 1S2D originated with Dr. Dennis Dwyer (NIH) and was adapted for growth as axenic amastigotes as described (17Goyard S. Segawa H. Gordon J. Showalter M. Duncan R. Turco S.J. Beverley S.M. Mol. Biochem. Parasitol. 2003; 130: 31-42Crossref PubMed Scopus (147) Google Scholar). A clonal derivative of this strain, LdBob (17Goyard S. Segawa H. Gordon J. Showalter M. Duncan R. Turco S.J. Beverley S.M. Mol. Biochem. Parasitol. 2003; 130: 31-42Crossref PubMed Scopus (147) Google Scholar), was provided by Dr. Stephen Beverley (Washington University, St. Louis, MO). LdBob promastigotes were cultured at 26 °C in purine-replete M199-based medium as detailed (17Goyard S. Segawa H. Gordon J. Showalter M. Duncan R. Turco S.J. Beverley S.M. Mol. Biochem. Parasitol. 2003; 130: 31-42Crossref PubMed Scopus (147) Google Scholar) or in a modified Dulbecco's Modified Eagle-Leishmania (DME-L) medium (18Iovannisci D.M. Ullman B. J. Parasitol. 1983; 69: 633-636Crossref PubMed Scopus (123) Google Scholar) that lacks bovine serum albumin and is supplemented with 10% dialyzed fetal bovine serum, 1 mm glutamine, 1× RPMI 1640 vitamin mix, 10 μm folate, 100 μm and μm Axenic amastigotes were cultured at °C as described (17Goyard S. Segawa H. Gordon J. Showalter M. Duncan R. Turco S.J. Beverley S.M. Mol. Biochem. Parasitol. 2003; 130: 31-42Crossref PubMed Scopus (147) Google Scholar). The characterization of LdBob or is and from the HGPRT, APRT, and XPRT and the used for their by the have been described (5Jardim A. Bergeson S.E. Shih S. Carter N. Lucas R.W. Merlin G. Myler P.J. Stuart K. Ullman B. J. Biol. Chem. 1999; 274: 34403-34410Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 15Hwang H.Y. Gilberts T. Jardim A. Shih S. Ullman B. J. Biol. Chem. 1996; 271: 30840-30846Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar). The construction and of the and targeting in the of the HGPRT and XPRT have also been described (5Jardim A. Bergeson S.E. Shih S. Carter N. Lucas R.W. Merlin G. Myler P.J. Stuart K. Ullman B. J. Biol. Chem. 1999; 274: 34403-34410Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 15Hwang H.Y. Gilberts T. Jardim A. Shih S. Ullman B. J. Biol. Chem. 1996; 271: 30840-30846Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar). The was created by the of XPRT in the vector with the of the The replacement was by the and of XPRT from and them the within D.J. Beverley S.M. Mol. Biochem. Parasitol. PubMed Scopus Google Scholar). generate of HGPRT and XPRT, the genes were by and the restriction within the provided by Dr. Stephen The were and The other and which a peroxisomal targeting signal 1 and and were as described (7Shih S. Hwang H.Y. Carter D. Stenberg P. Ullman B. J. Biol. Chem. 1998; 273: 1534-1541Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar, 8Zarella-Boitz J.M. Rager N. Jardim A. Ullman B. Mol Biochem. Parasitol. 2004; 134: 43-51Crossref PubMed Scopus (27) Google Scholar). now referred to as and genetic were LdBob and were created in LdBob using the targeting and gene replacement for the of these within an L. donovani (5Jardim A. Bergeson S.E. Shih S. Carter N. Lucas R.W. Merlin G. Myler P.J. Stuart K. Ullman B. J. Biol. Chem. 1999; 274: 34403-34410Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 15Hwang H.Y. Gilberts T. Jardim A. Shih S. Ullman B. J. Biol. Chem. 1996; 271: 30840-30846Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar). The Δhgprt/Δxprt double was of targeted gene The and were with and and parasites using (17Goyard S. Segawa H. Gordon J. Showalter M. Duncan R. Turco S.J. Beverley S.M. Mol. Biochem. Parasitol. 2003; 130: 31-42Crossref PubMed Scopus (147) Google Scholar). were selected by parasites medium of either or D.J. Beverley S.M. Mol. Biochem. Parasitol. PubMed Scopus Google Scholar), as for the drug of the targeting The and were and in the M199-based whereas the Δhgprt/Δxprt mutant was selected and in the modified medium described The and Δhgprt/Δxprt were all in the drugs for which they The Δhgprt/Δxprt line was also with or and selected in and either 100 μm hypoxanthine or 100 μm xanthine to generate the and These are and The Δhgprt/Δxprt line that was with was selected in and 100 μm hypoxanthine and is Δhgprt/Δxprt and of and were by J. T. a Scholar). to L. donovani HGPRT, APRT, and XPRT proteins have been described (3Allen T. Hwang H.Y. Wilson K. Hanson S. Jardim A. Ullman B. Mol Biochem. Parasitol. 1995; 74: 99-103Crossref PubMed Scopus (24) Google Scholar, 4Allen T.E. Hwang H.Y. Jardim A. Olafson R. Ullman B. Mol. Biochem. Parasitol. 1995; 73: 133-143Crossref PubMed Scopus (38) Google Scholar, 5Jardim A. Bergeson S.E. Shih S. Carter N. Lucas R.W. Merlin G. Myler P.J. Stuart K. Ullman B. J. Biol. Chem. 1999; 274: 34403-34410Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar), and were out as J. T. a Scholar). to the H. G. Mol. Biochem. Parasitol. 1996; PubMed Scopus Google Scholar) was provided by Dr. of of parasites were in phosphate-buffered in mm mm 1 mm and inhibitor by and by at at were of promastigote as described D.M. D. K. K. Ullman B. J. Biol. Chem. Full Text PDF PubMed Google Scholar), whereas amastigote were with that were not by These the of purine and and in of of purine were using the described D.M. D. K. K. Ullman B. J. Biol. Chem. Full Text PDF PubMed Google Scholar). were with and at a of 1 in either promastigote or amastigote medium μm purine bovine serum and each 1 cells were in PBS, in and Parasite metabolism of purines was by the of genetically to in purine all parasites were with PBS, in modified medium and at 26 °C for they were at a of in of modified 100 μm purine and dialyzed were at a of amastigote medium and 100 μm for and by promastigotes were in promastigote medium and in Dulbecco's modified medium supplemented with mm and 10% bone marrow-derived mouse macrophages, from and promastigotes were in of macrophage growth medium and at °C in a macrophages were 10 in to extracellular promastigotes which growth medium was and an the were with PBS, and macrophages were using the CA). were a using and with an and parasites were of macrophages were a using and with a The Δhgprt/Δxprt was created of with drug and of HGPRT and XPRT Because HGPRT and XPRT are within a in the L. donovani (5Jardim A. Bergeson S.E. Shih S. Carter N. Lucas R.W. Merlin G. Myler P.J. Stuart K. Ullman B. J. Biol. Chem. 1999; 274: 34403-34410Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar), the of both genes was with a the of HGPRT and the of XPRT, to create the double The was with to generate the and the was with to create the Δhgprt/Δxprt double The of was in medium μm dCF and 100 μm whereas the and of the double were isolated in medium dCF and 100 μm adenine as a purine were obtained within the of only were obtained the of in the were and in medium adenine and of the and Δhgprt/Δxprt the new that been created by the homologous gene replacement The of with and to the HGPRT and XPRT the presence of the restriction in the wild type and and absence in the Δhgprt/Δxprt The strain, as lacks a for HGPRT exhibits a signal at with the XPRT that the of the within the the HGPRT a of isolated of HGPRT, APRT, and XPRT are also and the are for the homologous of wild and Δhgprt/Δxprt the absence of HGPRT and XPRT in in which the gene been The and for which data are in also the proteins to the The of wild type and Δhgprt/Δxprt promastigote to purines were a Whereas wild type promastigotes were of all purine and the Δhgprt/Δxprt not guanine, guanosine, hypoxanthine, or to nucleotides. The double however, adenine and adenosine the or not dCF was to the to not in promastigote for The ability of promastigotes to purine and was also These the from the described the metabolism of in wild type cells not in the double and metabolism in both wild type and mutant cells the in the presence or absence of The ability of Δhgprt/Δxprt promastigotes to proliferate in purine sources was Whereas wild type parasites in modified medium with any of the purine or as a purine and growth of Δhgprt/Δxprt promastigotes only in adenine or adenosine in the presence of μm A number of mutant parasites were at the of the in adenine or adenosine the parasites in dCF these parasites were not of in the absence of dCF and not The double mutant not in xanthine, guanine, guanosine, inosine, or hypoxanthine, although a of growth was was as the purine in the presence of The Δhgprt/Δxprt parasites in and dCF were also not of of The in was with an of that is a inhibitor of the leishmanial J. Biol. Chem. 1999; 274: Full Text Full Text PDF PubMed Scopus Google Scholar). at μm the Δhgprt/Δxprt double to for in 100 μm inosine, growth in the combination also not not The Δhgprt/Δxprt and the growth as the and parasites all whereas all purines guanine, xanthine, and xanthosine not dCF was not necessary for growth with adenine or adenosine in the of the Δhgprt/Δxprt line also with of and that their glycosomal targeting (7Shih S. Hwang H.Y. Carter D. Stenberg P. Ullman B. J. Biol. Chem. 1998; 273: 1534-1541Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar, 8Zarella-Boitz J.M. Rager N. Jardim A. Ullman B. Mol Biochem. Parasitol. 2004; 134: 43-51Crossref PubMed Scopus (27) Google Scholar). The and in either hypoxanthine or xanthine that localization of either enzyme is not necessary for enzyme in the promastigote of the parasite (7Shih S. Hwang H.Y. Carter D. Stenberg P. Ullman B. J. Biol. Chem. 1998; 273: 1534-1541Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar, 8Zarella-Boitz J.M. Rager N. Jardim A. Ullman B. Mol Biochem. Parasitol. 2004; 134: 43-51Crossref PubMed Scopus (27) Google Scholar). wild type and Δhgprt/Δxprt parasites were of to axenic as by their of a family of H. G. Mol. Cell. Biol. PubMed Scopus Google Scholar). was in the The growth of both wild type and axenic amastigotes were to their promastigote not The metabolic of the axenic amastigotes purines were also from the promastigote type L. donovani promastigotes were of a of bone marrow-derived murine macrophages, whereas the Δhgprt/Δxprt not of the wild type strain was whereas the double infectivity was a The inability of Δhgprt/Δxprt cells to proliferate macrophages not to a to the mammalian of intracellular parasites were for both wild type and parasites not of the macrophage medium with either 100 μm adenine or a combination of 100 μm adenine μm dCF the Δhgprt/Δxprt mutant to a parasite of and that it is possible for the Δhgprt/Δxprt mutant to proliferate within macrophages are provided to host cells and also in the macrophages, although the infectivity was that of wild type Parasite of and were for and not The purine salvage pathway of Leishmania is and although which of the routes of purine salvage are has genetic dissection (1Marr J.J. Berens R.L. Nelson D.J. Biochim. Biophys. Acta. 1978; 544: 360-371Crossref PubMed Scopus (148) Google Scholar, R.L. Marr J.J. Marr J.J. M. and of Google Scholar). and gene replacement in L. donovani have that of the four enzymes of host purine or to the HGPRT, APRT, XPRT, or AK, is essential by (5Jardim A. Bergeson S.E. Shih S. Carter N. Lucas R.W. Merlin G. Myler P.J. Stuart K. Ullman B. J. Biol. Chem. 1999; 274: 34403-34410Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 15Hwang H.Y. Gilberts T. Jardim A. Shih S. Ullman B. J. Biol. Chem. 1996; 271: 30840-30846Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar, 16Hwang H.Y. Ullman B. J. Biol. Chem. 1997; 272: 19488-19496Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar, D.M. Ullman B. Mol. Biochem. Parasitol. PubMed Scopus Google Scholar). the ability to generate H.Y. Ullman B. J. Biol. Chem. 1997; 272: 19488-19496Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar) and L. donovani promastigotes that the parasite can either a XPRT or HGPRT for all of purine it has been possible to generate mutant parasites by targeted gene replacement in every conceivable combination a and These were the for our fundamental hypothesis that either HGPRT or XPRT is necessary and sufficient for Leishmania parasites to salvage viability, and sustain The hypothesis was by the inability to generate a Δhgprt/Δxprt double within a genetic with an of either HGPRT or M. and B. We now report genetic of our hypothesis by the creation and characterization of a conditional Δhgprt/Δxprt double of the of the HGPRT and XPRT genes in the leishmanial (5Jardim A. Bergeson S.E. Shih S. Carter N. Lucas R.W. Merlin G. Myler P.J. Stuart K. Ullman B. J. Biol. Chem. 1999; 274: 34403-34410Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar), a Δhgprt/Δxprt mutant was selected of targeted gene with the in the presence of 100 μm adenine and μm dCF, an inhibitor of the L. donovani (11Kidder G.W. Nolan L.L. Proc. Natl. Acad. Sci. U. S. A. 1979; 76: 3670-3672Crossref PubMed Scopus (41) Google Scholar). The Δhgprt/Δxprt mutant is absolutely the presence of dCF and either adenine or adenosine as a purine source for and other purine enable of either of the parasite. of by the double with adenine or adenosine in the absence of dCF, this not The ability of the Δhgprt/Δxprt to in adenine or adenosine can to the for to the source to is by that Δhgprt/Δxprt as well as parasites were of adenine or adenosine to the however, the of adenine or which is to adenine by L. donovani promastigotes (11Kidder G.W. Nolan L.L. Proc. Natl. Acad. Sci. U. S. A. 1979; 76: 3670-3672Crossref PubMed Scopus (41) Google Scholar, D.M. D. K. K. Ullman B. J. Biol. Chem. Full Text PDF PubMed Google Scholar, D.M. Ullman B. Mol. Biochem. Parasitol. PubMed Scopus Google Scholar), to hypoxanthine, a for Δhgprt/Δxprt The ability of the mutant promastigotes to in dCF or that L. donovani express an of the kinase has not been in Leishmania (1Marr J.J. Berens R.L. Nelson D.J. Biochim. Biophys. Acta. 1978; 544: 360-371Crossref PubMed Scopus (148) Google Scholar), a of the and has been in L. donovani promastigotes D.J. Berens R.L. Marr J.J. J. Biol. Chem. 1979; 254: Full Text PDF PubMed Google Scholar, P. Proc. Natl. Acad. Sci. U. S. A. 1983; PubMed Scopus Google Scholar). this is also of is not are effective to visceral leishmaniasis M. M. B. 73: PubMed Scopus Google Scholar). a strain with as a for the disease is a to leishmaniasis the of treatment with Previous studies using Leishmania or of Leishmania have that these are of a by Leishmania in M. M. B. 73: PubMed Scopus Google Scholar, Beverley S.M. P. J. 2004; PubMed Scopus Google Scholar). The inability of the Δhgprt/Δxprt to sustain an of murine macrophages this mutant strain as a for such a visceral The Δhgprt/Δxprt mutant infects macrophages at a <5% of that of wild type that the of the Δhgprt/Δxprt mutant in macrophages can by the of either adenine a combination of adenine and dCF, to the growth Thus, it to sustain an of the Δhgprt/Δxprt strain in by with adenine and/or dCF a has been The strain by of the is of to the of the mutant and studies are to the Δhgprt/Δxprt double mutant is and not by the parasite to adenine or adenosine We Dr. Stephen Beverley for the LdBob strain and Dr. Dr. and Dr. for the macrophages and for their We also Dr. and Dr. for with the and was a from Dr. L. of the of

References

29